Catalent Partnering with Multiple Customers on COVID-Related Vaccines and TherapiesIncluding Johnson & Johnson, AstraZeneca, Moderna and Humanigen Learn More Expertise Across Various Cell TypesOur comprehensive cell therapy portfolio spans a wide range of cell types including CAR-T, TCR, TILs, and more Learn More €90M+ Invested in European CapabilitiesIntegrated development, manufacturing and packaging of biologics and sterile injectables Learn More Catalent Partnering with Multiple Customers on COVID-Related Vaccines and TherapiesIncluding Johnson & Johnson, AstraZeneca, Moderna and Humanigen Learn More Expertise Across Various Cell TypesOur comprehensive cell therapy portfolio spans a wide range of cell types including CAR-T, TCR, TILs, more Learn More €90M+ Invested in European CapabilitiesIntegrated development, manufacturing and packaging of biologics and sterile injectables Learn More How can we work together BiologicsDevelopment Gene Therapy Cell Therapy Technologies Latest News Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology CATALENT RESPONDS TO THE GLOBAL COVID-19 OUTBREAK We are taking decisive action to minimize the impact of the COVID-19 pandemic on our employees, partners, customers, and their patients. LEARN MORE Cell Therapy With our advanced technologies and expertise in both autologous and allogeneic development and manufacturing, Catalent is your full-service partner for CAR-T immunotherapies and beyond. Gene Therapy With experience across more than 60 gene therapy programs and leading expertise in AAV Vectors, Catalent’s Gene Therapy team will provide you with full life cycle support of your life-saving therapeutic. STRATEGIES TO ACHIEVE SUCCESSFUL COMMERCIAL APPROVAL & LAUNCH Experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the successful launch and approval of a biologic. Biologics Network Our network of biologics sites provides an integrated approach to get medicines to your patients faster anywhere in the world. SEE ALL LOCATIONS Join Our Team Catalent is growing in Biologics and is making significant investments in people in this area. Explore global career opportunities with our Biologics team. NEWS Catalent Biologics and Humanigen to Present a Case Study on Accelerated Scale Up of a Monoclonal Antibody to Treat COVID-19 at BioProcess International Conference Catalent Invests $130 Million to Add Additional Manufacturing Capacity at its Gene Therapy Campus in Harmans, Maryland Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility VIEW ALL NEWS EVENTS BioProcess International World Vaccine Congress Endpoints 11 Awards: Startups to Watch PDA Universe of Pre-Filled Syringes and Injection Devices VIEW ALL EVENTS EXPERT CONTENT Advances in Analytical Technology for Biopharmaceuticals Prefilled Syringes & Parental Manufacturing Accelerating Method Transfer: Effective Automation Of Biological Assays VIEW ALL ARTICLES
